Genflow Biosciences Files Patent Examination Request in China for SIRT6-Based NASH Therapy
核心洞察
Genflow Biosciences (搜索) has submitted a formal request for patent examination in China for proprietary SIRT6 (搜索) variants designed to treat Non-Alcoholic Steatohepatitis (搜索) (NASH (搜索)).
The filing strengthens the company's global intellectual property portfolio for SIRT6 (搜索)-based gene therapies targeting the severe progressive liver disease.
NASH (搜索) represents a significant unmet medical need with limited treatment options, and Genflow believes its approach could transform the treatment landscape.
Genflow Biosciences (搜索) PLC has submitted a formal request for examination of its patent application in China relating to proprietary SIRT6 (搜索) variants designed for the treatment of Non-Alcoholic Steatohepatitis (搜索) (NASH (搜索)), a severe and progressive liver disease. The filing represents a strategic expansion of the company's intellectual property protection into one of the world's largest healthcare markets.
Strengthening Global IP Portfolio
The patent application covers proprietary variants of the SIRT6 (搜索) gene specifically designed to address NASH (搜索), a condition with limited treatment options currently available. By pursuing examination in China, Genflow is reinforcing its global intellectual property portfolio and furthering its commitment to developing innovative therapies for patients worldwide.
Dr. Eric Leire, CEO of Genflow, commented: "The filing of this examination request in China represents another significant step in protecting our technology in one of the world's largest healthcare markets. We are committed to advancing our research into SIRT6 (搜索)-based therapies and believe that our approach holds strong potential to transform the treatment landscape for NASH (搜索)."
SIRT6-Based Gene Therapy Platform
Founded in 2020, Genflow Biosciences (搜索) is a biotechnology company headquartered in the UK with R&D facilities in Belgium, pioneering gene therapies to decelerate the aging process. The company's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 (搜索) gene which has yielded promising preclinical results.
Clinical Development Timeline
Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6 (搜索)-centenarian gene therapy in aged dogs began in March 2025. Other programs planned for 2025 include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (搜索) (Metabolic Dysfunction-Associated Steatohepatitis (搜索)), described as the most prevalent chronic liver disease for which there are no effective treatments.
Addressing Unmet Medical Need
The company believes its SIRT6 (搜索)-based therapies have the potential to transform the treatment landscape for NASH (搜索), addressing a condition with significant unmet medical need. NASH is characterized as a severe progressive liver disease with limited treatment options, representing a substantial opportunity for therapeutic intervention.
The patent filing in China underscores Genflow's strategic approach to protecting its innovative gene therapy technology across major global markets as it advances toward clinical development of treatments for liver diseases with significant unmet medical needs.